Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience

Leuk Lymphoma. 2019 Oct;60(10):2483-2487. doi: 10.1080/10428194.2019.1581930. Epub 2019 Mar 7.

Abstract

Myelodysplastic syndrome unclassifiable (MDS-U) is a small subtype of myelodysplastic syndromes (MDS). However, rare literature exists in terms of natural progression and clinical outcome of patients with MDS-U. In the present study, we investigated the characteristics and the clinical outcomes of patients categorized as MDS-U based on 2008 World Health Organization criteria (WHO) in a single center comparing to other MDS groups. Out of eight hundred and two patients who met WHO criteria for MDS at our institution, ninety patients (11%) were initially classified as MDS-U. Upon pathological review, only half of the cases were confirmed to be MDS-U. With follow up, half of the MDS-U cases were reclassified to another subtype. We found neither significant difference in median overall survival nor in risk of transformation to acute myeloid leukemia when comparing MDS-U to other MDS groups. Additional larger studies are needed to confirm our results.

Keywords: Myelodysplastic syndrome; World Health Organization; overall survival; unclassifiable.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers
  • Biopsy
  • Bone Marrow / pathology
  • Disease Management
  • Disease Progression
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / diagnosis*
  • Myelodysplastic Syndromes / epidemiology*
  • Myelodysplastic Syndromes / mortality
  • Patient Outcome Assessment
  • Public Health Surveillance
  • Retrospective Studies
  • Survival Analysis

Substances

  • Biomarkers